Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An international, prospective, multicentre, observational study to evaluate the long-term safety profile of alemtuzumab treatment in patients with relapsing-remitting multiple-sclerosis (RRMS) in real life

Next Previous
Trial Profile

An international, prospective, multicentre, observational study to evaluate the long-term safety profile of alemtuzumab treatment in patients with relapsing-remitting multiple-sclerosis (RRMS) in real life

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms PASS

Most Recent Events

  • 28 Jun 2022 Results (n=3024; data cut-off Dec-2019) assessing the incidence of adverse events (AEs) following alemtuzumab treatment to further characterize its long-term safety profile, presented at the 8th Congress of the European Academy of Neurology.
  • 26 Jul 2017 New trial record
  • 27 Jun 2017 Trial design of the study presented at the 3rd Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top